Research programme: chromatin modifying protein inhibitors - Epizyme
Latest Information Update: 18 Mar 2016
At a glance
- Originator Epizyme
- Class Small molecules
- Mechanism of Action Protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer